Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Plecanatide (Trulance) vs Sincalide (Kinevac)
An educational, source-based comparison of Plecanatide (Trulance) and Sincalide (Kinevac) — how each peptide works, what it's researched for, and what to know before going deeper.
Synthetic analog of human uroguanylin that activates guanylate cyclase-C in a pH-dependent manner, increasing intestinal fluid secretion and transit.
- Chronic idiopathic constipation
- IBS-C
- • FDA-approved.
- • Diarrhea most common adverse event.
Synthetic C-terminal octapeptide of cholecystokinin for gallbladder imaging.
Synthetic CCK-8 that binds CCK-A receptors on gallbladder smooth muscle, triggering contraction; used to assess gallbladder ejection fraction in cholescintigraphy.
- Gallbladder ejection fraction (HIDA scan)
- Pancreatic secretion testing
- Small bowel transit imaging
- • FDA-approved.
- • Abdominal cramping, nausea, diarrhea common; contraindicated in suspected gallstone obstruction.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Plecanatide (Trulance) | Plecanatide phase 3 | American Journal of Gastroenterology | 2017 | Significantly improved complete spontaneous bowel movements vs placebo. |
| Sincalide (Kinevac) | Standardized sincalide cholescintigraphy guideline | J Nucl Med | 2010 | Established 60-minute infusion as optimal for reproducible GBEF. |
Side-effect & safety grid
- FDA-approved.
- Diarrhea most common adverse event.
- FDA-approved.
- Abdominal cramping, nausea, diarrhea common; contraindicated in suspected gallstone obstruction.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Plecanatide (Trulance) vs Sincalide (Kinevac) — Key differences
- Class: Plecanatide (Trulance) is classified as GC-C Agonist · Gastrointestinal, while Sincalide (Kinevac) is CCK Analog · Diagnostics.
- Primary research focus: Plecanatide (Trulance) — chronic idiopathic constipation; Sincalide (Kinevac) — gallbladder ejection fraction (hida scan).
- Tag: FDA-Approved · GI vs FDA-Approved · Diagnostics.